European Trial of Immunosuppression in SPK Tx

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00140543
Recruitment Status : Unknown
Verified August 2005 by EUROSPK Study Group.
Recruitment status was:  Active, not recruiting
First Posted : September 1, 2005
Last Update Posted : November 18, 2005
Fujisawa GmbH
Hoffmann-La Roche
Wyeth is now a wholly owned subsidiary of Pfizer
Neovii Biotech
Genzyme, a Sanofi Company
Information provided by:
EUROSPK Study Group

August 31, 2005
September 1, 2005
November 18, 2005
February 2002
Not Provided
At 1 year:Incidence of biopsy-proven (kidney) rejection episodes.
Same as current
Complete list of historical versions of study NCT00140543 on Archive Site
  • SECONDARY ENDPOINTS: At 6 months and 1 year
  • * Kidney/Pancreas function (at 6 months and 1 year):
  • - Kidney function will be measured by:
  • - S- creatinine
  • - Creatinine clearance
  • - Pancreas function will be measured by:
  • - Fasting Glucose level (< 123 mg/dl)
  • - HbA1C
  • - Need for insulin therapy
  • - Need for oral drugs
  • * At 6 months and 1 year:
  • - Patient and graft survival
  • - Lipid profile
  • - Infections
  • - Side effects
  • - Blood Pressure
  • - Treatment failure for any reason, such as permanent discontinuation of a drug, graft loss or death.
  • * % of steroid free patients: at 6 months and 1 year.
Same as current
Not Provided
Not Provided
European Trial of Immunosuppression in SPK Tx
A European Multicenter Open-Label Randomised Trial to Evaluate the Efficacy and Safety of Sirolimus and Tacrolimus Compared to MMF and Tacrolimus With Short-Course Induction Therapy, Short-Term Steroids Application in De Novo SPK Transplanted Diabetic Patients
  1. To determine and compare the efficacy of Tacrolimus/Rapa versus Tacrolimus/MMF-based immunosuppression (in conjunction with initial short-term steroids and polyclonal antibody administration) in Type 1-diabetic patients undergoing simultaneous pancreas/kidney allograft transplantation.
  2. To evaluate the safety of Tacrolimus/Rapa versus Tacrolimus/MMF in terms of drug-related complications and overimmunosuppression-associated complications, particularly under monitoring of the pharmacokinetic profile of all drugs administered.
This will be a controlled, randomised study, to be performed in 15-20 pancreas transplantation centers throughout Europe. Patients will be randomised into one of two treatment groups. Group 1 will receive Tacrolimus and Mycophenolate Mofetil (= best group in EuroSPK001 trial). Group 2 will receive Tacrolimus and Sirolimus. Both groups will receive in association short-term corticosteroids and polyclonal antibody preparation. Patients will be randomly assigned to one of the 2 treatment groups in a 1:1 ratio before transplantation. The study will last 3 years, with a first interim analysis of the data at 6 months and a complete analysis at 1 year.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Diabetes Mellitus, Type 1
  • Diabetic Nephropathy
Drug: sirolimus versus mycophenolate mofetil
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
April 2008
Not Provided

Inclusion Criteria:

  1. Male or female patients, of 18 to 55 years of age, with end-stage, C-peptide-negative, Type 1-diabetic nephropathy.
  2. Female patients of childbearing age must have a negative pregnancy test and must agree to maintain effective birth control practice throughout the study period (3 years).
  3. Patient must have signed the Patient Informed Consent Form.
  4. Patient must receive a primary simultaneous pancreas/kidney (SPK) cadaveric transplant, with either intestinal or bladder and either portal or systemic venous drainages.

Exclusion Criteria:

  1. Patient is pregnant or breastfeeding.
  2. Patient is allergic or intolerant to Mycophenolate Mofetil, Sirolimus, Tacrolimus or other macrolides, or any compounds structurally related to these compounds.
  3. Patient has a positive T-cell crossmatch on the most recent serum specimen.
  4. Patient is known for active liver disease or has significant liver disease, defined by ASAT and ALAT serum levels greater than 3 times the upper limit of normal.
  5. Patient has malignancy or history of malignancy, with the exception of adequately treated localised squamous cell or basal cell carcinoma, without recurrence.
  6. Patient has been included in another clinical trial protocol for any investigational drug within 4 weeks prior to randomisation.
  7. Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication.
  8. Patient receives a SPK transplant from a living donor, or receives segmental pancreatic transplant, or a previous kidney transplant alone.
  9. Pancreatic duct occlusion technique .
  10. Donor is older than 55 years of age.

Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Austria,   Belgium,   Czech Republic,   Germany,   Israel,   Spain,   Switzerland
Not Provided
Not Provided
Not Provided
Not Provided
EUROSPK Study Group
  • Fujisawa GmbH
  • Hoffmann-La Roche
  • Wyeth is now a wholly owned subsidiary of Pfizer
  • Neovii Biotech
  • Genzyme, a Sanofi Company
EUROSPK Study Group
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP